Literature DB >> 21607190

In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes.

James J Leyden, Norman Preston, Cris Osborn, Ronald W Gottschalk.   

Abstract

BACKGROUND: A gel combination treatment containing a retinoid (adapalene 0.1%) and an antimicrobial (benzoyl peroxide 2.5%) has been shown to be an effective treatment for acne vulgaris, addressing three of the four pathogenic factors (hyperkeratinization, Propionibacterium acnes proliferation, inflammation) without contributing to the incidence of Propionibacterium acnes antibiotic resistance as neither the retinoid nor benzoyl peroxide creates selective pressure for resistance.
OBJECTIVE: To evaluate the effectiveness of an adapalene-benzoyl peroxide gel combination in reducing antibiotic-sensitive and resistant strains of Propionibacterium acnes on the facial skin of volunteers.
METHODS: This four-week, open-label, single-center study included 30 healthy adults with high facial Propionibacterium acnes populations [>10(4) colony-forming units per square centimeter of skin (CFU/cm(2))] and presence of subpopulations resistant to erythromycin, tetracycline, and clindamycin. The gel was applied once daily to the forehead. Cultures for total and antibiotic-resistant Propionibacterium acnes were obtained from the forehead area at screening, Baseline, Week 2, and Week 4.
RESULTS: Total Propionibacterium acnes counts decreased by 1.1 log(10) CFU/cm(2) after two weeks of treatment, and by 1.6 log10 CFU/cm(2) after four weeks. All subjects had strains resistant to each of the five antibiotics at baseline. Mean counts of erythromycin and clindamycin resistant Propionibacterium acnes were high at baseline (5.37 and 5.28 log(10) CFU/cm(2), respectively) and decreased by ≥2.1 log(10) by Week 4 (P<0.001). Mean counts of strains resistant to tetracyclines were lower at baseline (3.8 to 4.2 CFU/cm(2)) and decreased by 1.9 (tetracycline), 2.4 (minocycline), and 1.3 (doxycycline) log(10) CFU/cm(2) by Week 4 (P<0.001). LIMITATIONS: Although limited in scope, the results of the present study demonstrate that the fixed-dose combination gel containing adapalene 0.1% and benzoyl peroxide 2.5% effectively inhibited both antibiotic-susceptible and antibiotic-resistant Propionibacterium acnes. In addition to reducing population densities, therapy with adapalene-benzoyl peroxide eradicated some resistant strains entirely in some individual subjects.
CONCLUSION: Topical adapalene-benzoyl peroxide gel effectively reduced skin colonization by antibiotic-sensitive and antibiotic-resistant Propionibacterium acnes after four weeks. This trial was registered with ClinicalTrials.gov (http://clinicaltrials.gov/), registry number NCT00907101.

Entities:  

Year:  2011        PMID: 21607190      PMCID: PMC3100113     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  40 in total

1.  Topical drug treatment in acne.

Authors:  H Gollnick; M Schramm
Journal:  Dermatology       Date:  1998       Impact factor: 5.366

2.  Investigations on the bacteriostatic effect of benzoyl peroxide.

Authors:  D Fanta; H Bardach; C Poitscheck
Journal:  Arch Dermatol Res       Date:  1979-05-04       Impact factor: 3.017

3.  'Keratolytic' properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man.

Authors:  J M Waller; F Dreher; S Behnam; C Ford; C Lee; T Tiet; G D Weinstein; H I Maibach
Journal:  Skin Pharmacol Physiol       Date:  2006-06-16       Impact factor: 3.479

4.  Digital fluorescence photography can assess the suppressive effect of benzoyl peroxide on Propionibacterium acnes.

Authors:  A Pagnoni; A M Kligman; N Kollias; S Goldberg; T Stoudemayer
Journal:  J Am Acad Dermatol       Date:  1999-11       Impact factor: 11.527

Review 5.  A current review of topical benzoyl peroxide: new perspectives on formulation and utilization.

Authors:  Emil A Tanghetti; Karl F Popp
Journal:  Dermatol Clin       Date:  2009-01       Impact factor: 3.478

Review 6.  Microbiology's principle of biofilms as a major factor in the pathogenesis of acne vulgaris.

Authors:  Craig N Burkhart; Craig G Burkhart
Journal:  Int J Dermatol       Date:  2003-12       Impact factor: 2.736

Review 7.  Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability.

Authors:  Tarek Fakhouri; Brad A Yentzer; Steven R Feldman
Journal:  J Drugs Dermatol       Date:  2009-07       Impact factor: 2.114

8.  A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne.

Authors:  Linda Stein Gold; Jerry Tan; Alma Cruz-Santana; Kim Papp; Yves Poulin; Joel Schlessinger; Judi Gidner; Yin Liu; Michael Graeber
Journal:  Cutis       Date:  2009-08

9.  Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure.

Authors:  E A Eady; J H Cove; K T Holland; W J Cunliffe
Journal:  Br J Dermatol       Date:  1989-07       Impact factor: 9.302

10.  Antibiotic-resistant acne: lessons from Europe.

Authors:  J I Ross; A M Snelling; E Carnegie; P Coates; W J Cunliffe; V Bettoli; G Tosti; A Katsambas; J I Galvan Peréz Del Pulgar; O Rollman; L Török; E A Eady; J H Cove
Journal:  Br J Dermatol       Date:  2003-03       Impact factor: 9.302

View more
  10 in total

1.  Efficacy and Safety of Tazarotene 0.1% Plus Clindamycin 1% Gel Versus Adapalene 0.1% Plus Clindamycin 1% Gel in Facial Acne Vulgaris: A Randomized, Controlled Clinical Trial.

Authors:  Rituparna Maiti; Chandra Sekhar Sirka; M A Ashique Rahman; Anand Srinivasan; Sansita Parida; Debasish Hota
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

2.  Cutibacterium acnes Isolates from Deep Tissue Specimens Retrieved during Revision Shoulder Arthroplasty: Similar Colony Morphology Does Not Indicate Clonality.

Authors:  Roger E Bumgarner; Della Harrison; Jason E Hsu
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

3.  Minimum Contact Time of 1.25%, 2.5%, 5%, and 10% Benzoyl Peroxide for a Bactericidal Effect Against Cutibacterium acnes.

Authors:  Punyanun Boonchaya; Salinee Rojhirunsakool; Nanticha Kamanamool; Saranya Khunkhet; Surasak Yooyongsatit; Montree Udompataikul; Malai Taweechotipatr
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-03-10

4.  A small peptide with therapeutic potential for inflammatory acne vulgaris.

Authors:  Zhiye Zhang; Lixian Mu; Jing Tang; Zilei Duan; Fengyu Wang; Lin Wei; Mingqiang Rong; Ren Lai
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

5.  BMAL1 regulates Propionibacterium acnes-induced skin inflammation via REV-ERBα in mice.

Authors:  Feng Li; Luomin Lin; Yiting He; Guanghui Sun; Dong Dong; Baojian Wu
Journal:  Int J Biol Sci       Date:  2022-03-21       Impact factor: 6.580

6.  Liposomal encapsulated rhodomyrtone: a novel antiacne drug.

Authors:  Julalak Chorachoo; Thanaporn Amnuaikit; Supayang P Voravuthikunchai
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

7.  Cross-sectional Pilot Study of Antibiotic Resistance in Propionibacterium Acnes Strains in Indian Acne Patients Using 16S-RNA Polymerase Chain Reaction: A Comparison Among Treatment Modalities Including Antibiotics, Benzoyl Peroxide, and Isotretinoin.

Authors:  Kabir Sardana; Tanvi Gupta; Bipul Kumar; Hemant K Gautam; Vijay K Garg
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

Review 8.  Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review.

Authors:  Theresa N Canavan; Edward Chen; Boni E Elewski
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-19

9.  Efficacy and Safety of VB-1953 Topical Gel in Non-Responder Acne Patients with Clindamycin-Resistant Cutibacterium acnes.

Authors:  Rohit Batra; Suresh Sadhasivam; Swamini Saini; Swati Gupta; Rahul Kumar Singh Bisen; Mau Sinha; Shamik Ghosh; Shilpi Jain
Journal:  Drugs R D       Date:  2020-06

10.  Bactericidal efficacy of hydrogen peroxide on Cutibacterium acnes.

Authors:  P Hernandez; B Sager; A Fa; T Liang; C Lozano; M Khazzam
Journal:  Bone Joint Res       Date:  2019-02-02       Impact factor: 5.853

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.